Second Recognition in Four Years Highlights the Significance of MiSight® 1 day Clinical Trial
Findings
ROCHESTER, N.Y., September 25, 2025—CooperVision’s research and development team, led by Senior Director of Research Programs Paul Chamberlain, along with their coauthors, has once again received the prestigious Garland W. Clay Award, presented annually by the American Academy of Optometry. This marks the second time in four years that CooperVision’s pioneering work in myopia control has received the honor, underscoring the company’s enduring leadership and impact in advancing eye health worldwide.
The 2025 award recognizes the paper, “Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial” (Chamberlain P. et al.), published in Optometry and Vision Science (OVS). The award honors the authors of the most significant paper in OVS over the past five years: Paul Chamberlain, Arthur Bradley, Baskar Arumugam, David Hammond and John McNally, CooperVision; Nicola S. Logan, Aston University, United Kingdom; Deborah Jones, University of Waterloo, Canada; Cheryl Ngo, National University Hospital, Singapore; Sofia C. Peixoto-De-Matos, University of Minho, Portugal; Chris Hunt and Graeme Young, Visioncare Research, United Kingdom.
“I am incredibly honored, along with my coauthors, to receive the Garland W. Clay Award for a second time in such a short period,” said Chamberlain. “We are passionate about sharing the MiSight® 1 day study findings with the global eye care professional community, presenting research that is balanced, clinically meaningful, and practical, which are all values Garland Clay championed. This recognition also belongs to the investigators, staff, children and their families whose long-term commitment was essential to every insight we’ve shared.”
This six-year publication, the second installment in the trilogy of landmark MiSight® 1 day clinical trial papers, demonstrated the sustained treatment effect of the lens in slowing myopia progression, reinforcing its clinical value.*1 It follows the three-year results paper, which earned the 2021 Garland W. Clay Award, and precedes the publication of the findings of the final year of the seven-year study, completing the longest continuous investigation of its kind for myopia control contact lenses. Collectively, the trilogy provides unmatched evidence of MiSight® 1 day’s safety2 and effectiveness in slowing the progression of myopia in children.3
“To be recognized with the Garland W. Clay Award for a second time is an extraordinary testament to the quality, impact, and enduring relevance of our research,” said Jennifer Lambert, Vice President, Myopia Management & Cornea Care, CooperVision. “This three-part study not only shaped the global scientific conversation around myopia management but also translated into real-world benefits for children and families worldwide.”
“The American Academy of Optometry will formally present the 2025 Garland W. Clay Award to the authors on Friday, October 10, during its annual meeting in Boston. The publication is available online via Open Access.
###
* While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.
1 Chamberlain P, et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci. 2022 Mar 1;99(3):204-212.
2 Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391.
3 Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Laura DiCaprio, APR, Associate Director
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153